Pregnancy, thrombophilia, and the risk of a first venous thrombosis: Systematic review and bayesian meta-analysisCroles, F. N., Nasserinejad, K., Duvekot, J. J., Kruip, M. J. H. A., Meijer, K. & Leebeek, F. W. G., 26-Oct-2017, In : British Medical Journal. 359, 12 p., 4452.
Research output: Contribution to journal › Review article › Academic › peer-review
Objective: To provide evidence to support updated guidelines for the management of pregnant women with hereditary thrombophilia in order to reduce the risk of a first venous thromboembolism (VTE) in pregnancy.
Design: Systematic review and bayesian meta-analysis.
Data sources: Embase, Medline, Web of Science, Cochrane Library, and Google Scholar from inception through 14 November 2016.
Review methods: Observational studies that reported on pregnancies without the use of anticoagulants and the outcome of first VTE for women with thrombophilia were eligible for inclusion. VTE was considered established if it was confirmed by objective means, or when the patient had received a full course of a full dose anticoagulant treatment without objective testing.
Results: 36 studies were included in the meta-analysis. All thrombophilias increased the risk for pregnancy associated VTE (probabilities = 91%). Regarding absolute risks of pregnancy associated VTE, high risk thrombophilias were antithrombin deficiency (antepartum: 7.3%, 95% credible interval 1.8% to 15.6%; post partum: 11.1%, 3.7% to 21.0%), protein C deficiency (antepartum: 3.2%, 0.6% to 8.2%; post partum: 5.4%, 0.9% to 13.8%), protein S deficiency (antepartum: 0.9%, 0.0% to 3.7%; post partum: 4.2%; 0.7% to 9.4%), and homozygous factor V Leiden (antepartum: 2.8%, 0.0% to 8.6%; post partum: 2.8%, 0.0% to 8.8%). Absolute combined antepartum and postpartum risks for women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutations, or compound heterozygous factor V Leiden and prothrombin G20210A mutations were all below 3%.
Conclusions: Women with antithrombin, protein C, or protein S deficiency or with homozygous factor V Leiden should be considered for antepartum or postpartum thrombosis prophylaxis, or both. Women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutation, or compound heterozygous factor V Leiden and prothrombin G20210A mutation should generally not be prescribed thrombosis prophylaxis on the basis of thrombophilia and family history alone. These data should be considered in future guidelines on pregnancy associated VTE risk.
|Number of pages||12|
|Journal||British Medical Journal|
|Publication status||Published - 26-Oct-2017|
- FACTOR-V-LEIDEN, VTE